Global mAb Biosimilars Market 2016-2020

Publisher Name :
Date: 23-Sep-2016
No. of pages: 103
Inquire Before Buying

Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.

The analysts forecast spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of more than 57% during the period 2015-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.

The market is divided into the following segments based on geography:


  • Europe

  • Asia

  • ROW


The report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • Biocon

  • Celltrion

  • Dr. Reddy's Laboratories

  • Hospira


Other prominent vendors


  • 3SBio

  • Accord Healthcare

  • AET Biotech

  • Allergan

  • Alvartis Pharma

  • Amega Biotech

  • Amgen

  • Apotex

  • Aspen

  • AstraZeneca

  • Aurobindo Pharma

  • Baxter

  • Bharat Serums

  • Bio Sidus

  • Biogen

  • Bionovis

  • Bioton

  • BioXpress Therapeutics

  • Boehringer Ingelheim

  • Boston Oncology

  • Cipla

  • Coherus Biosciences

  • Daiichi Sankyo

  • Emcure Pharmaceuticals

  • Gedeon Richter

  • GeneScience Pharmaceuticals

  • GSK

  • Hetero Drugs

  • iBio

  • Intas Pharmaceuticals

  • JCR Pharmaceuticals

  • LG Lifesciences

  • Lonza

  • Merck

  • Mitsubishi Tanabe Pharma

  • Momenta Pharmaceuticals

  • Mylan

  • Natco Pharma

  • Novartis

  • Pfenex

  • Pfizer

  • Ranbaxy Laboratories

  • Roche Holding

  • Samsung Biologics

  • Sanofi

  • Synthon


Market driver


  • •Rise in number of patent expiries

  • For a full, detailed list, view our report


Market challenge


  • Physicians' reluctance to prescribe biosimilars

  • For a full, detailed list, view our report


Market trend


  • Emergence of biosimilars

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2020 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Global mAb Biosimilars Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings
Assumptions

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights
Biosimilars: Overview
Comparative analysis of generic small molecules and biosimilars
Biosimilars market opportunities
Challenges for new entrants
Bio-betters

PART 05: Pipeline portfolio

PART 06: Market landscape
Market overview
Five forces analysis

PART 07: Market segmentation by application
Global chronic and autoimmune diseases mAb biosimilars market
Global oncology mAb biosimilars market

PART 08: Geographical segmentation
Global mAb biosimilars market by geographical segmentation 2015-2020
mAb biosimilars market in Europe
mAb biosimilars market in Asia
mAb biosimilars market in rest of the world

PART 09: Market drivers
Rise in number of patent expiries
Need for cost-effective treatment
Reimbursement benefits for biosimilars
Favorable government regulations

PART 10: Impact of drivers

PART 11: Market challenges
Physicians' reluctance to prescribe biosimilars
Multiple manufacturing complexities
Risks related to drug failure
Limited availability of biosimilar products
Difficulties in patient recruitment for clinical trials

PART 12: Impact of drivers and challenges

PART 13: Market trends
Emergence of biosimilars
Outsourcing of manufacturing activities
Need for high investment in R&D
High growth in the emerging markets
Rising number of strategic collaborations

PART 14: Vendor landscape
Competitive scenario

PART 15: Key vendor analysis
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
Other prominent vendors

PART 16: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Global mAb biosimilars market: Snapshot
Exhibit 03: Global mAb biosimilars market: Growth analysis
Exhibit 04: Global mAb biosimilars market: Key buying criteria 2015
Exhibit 05: Global mAb biosimilars market: Timeline 2014-2020
Exhibit 06: Global mAb biosimilars market: Impact of key customer segments 2015
Exhibit 07: Definition of biosimilars by agencies
Exhibit 08: Comparison between generic small molecules and biosimilars
Exhibit 09: Impact of biosimilars cost savings on different sectors
Exhibit 10: Factors affecting success of biosimilars
Exhibit 11: Biosimilars industry: Point-of-view
Exhibit 12: Factors influencing uptake of biosimilars
Exhibit 13: Global mAb biosimilars market: Strategic factors for new market entrants
Exhibit 14: Challenges for new entrants
Exhibit 15: Bio-betters and its impact on market
Exhibit 16: Global mAb biosimilars market: Pipeline snapshot 2015
Exhibit 17: Pipeline portfolio: Global mAb biosimilars market 2015
Exhibit 18: Patent expiry in key mAb biosimilars markets 2000-2020
Exhibit 19: Global mAb biosimilars market: Developed and emerging markets 2015
Exhibit 20: Global mAb biosimilars market 2015-2020 ($ millions)
Exhibit 21: Biosimilars: Savings potential in five European countries and US ($ billions) 2016-2020
Exhibit 22: Global spending on mAb biosimilars 2010-2020 ($ billions)
Exhibit 23: Global mAb biosimilars market: Key metrics analysis snapshot
Exhibit 24: Current and future trends in global mAb biosimilars market
Exhibit 25: Factors influencing the global mAb biosimilars market 2015
Exhibit 26: Five forces analysis
Exhibit 27: Global mAb biosimilars market: Segmentation by application (2015-2020)
Exhibit 28: Applications of mAb biosimilars and its impact on growth of market
Exhibit 29: Global mAb biosimilars market segmentation: Growth cycle analysis
Exhibit 30: Population aged 60 years and over (millions)
Exhibit 31: Global chronic and autoimmune diseases mAb biosimilars market 2015-2020 ($ millions)
Exhibit 32: Opportunity analysis of chronic and autoimmune diseases mAb biosimilars market by application
Exhibit 33: Global incidence of cancer 2015-2020 (millions)
Exhibit 34: Global oncology mAb biosimilars market 2015-2020 ($ millions)
Exhibit 35: Opportunity analysis of global oncology mAb biosimilars market by type of application
Exhibit 36: Global mAb biosimilars market segmentation by application 2015
Exhibit 37: Global mAb biosimilars market by geography: Outlook 2015-2020
Exhibit 38: Global mAb biosimilars market by geography 2015
Exhibit 39: Market penetration of originators and biosimilars by region/country
Exhibit 40: Global mAb biosimilars market landscape: Country analysis
Exhibit 41: mAb biosimilars market in Europe: Opportunity analysis
Exhibit 42: mAb biosimilars market in Europe 2015-2020 ($ millions)
Exhibit 43: PEST analysis: mAb biosimilars market in Europe 2015
Exhibit 44: mAb biosimilars market in Asia: Opportunity analysis
Exhibit 45: mAb biosimilars market in Asia 2015-2020 ($ millions)
Exhibit 46: PEST analysis: mAb biosimilars market in Asia 2015
Exhibit 47: mAb biosimilars market in rest of the world: Opportunity analysis
Exhibit 48: mAb biosimilars market in rest of the world 2015-2020 ($ millions)
Exhibit 49: Benefits of mAb biosimilars to US healthcare system
Exhibit 50: PEST analysis: mAb biosimilars market in rest of the world 2015
Exhibit 51: Impact of drivers and challenges on global mAb biosimilars market
Exhibit 52: Patent analysis of mAb in the US
Exhibit 53: Patent analysis of biologicals in Europe
Exhibit 54: Impact of drivers
Exhibit 55: Physicians' reluctance to prescribe biosimilars: Key reasons
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Global mAb biosimilars market: Impact assessment of key trends
Exhibit 58: Competitive assessment of vendors
Exhibit 59: Key vendors: Geographical presence 2015
Exhibit 60: Major vendors in global mAb biosimilars market: Mergers, acquisitions, and partnerships
Exhibit 61: Biocon profile
Exhibit 62: Biocon: Metrics analysis
Exhibit 63: Biocon growth strategy matrix
Exhibit 64: Biocon: Opportunity assessment
Exhibit 65: Celltrion profile
Exhibit 66: Celltrion: Metrics analysis
Exhibit 67: Celltrion growth strategy matrix
Exhibit 68: Celltrion: opportunity assessment
Exhibit 69: Dr. Reddy's Laboratories profile
Exhibit 70: Dr. Reddy's Laboratories: Metrics analysis
Exhibit 71: Dr. Reddy's Laboratories growth strategy matrix
Exhibit 72: Dr. Reddy's Laboratories Opportunity assessment
Exhibit 73: Hospira profile
Exhibit 74: Hospira: Metrics analysis
Exhibit 75: Hospira growth strategy matrix
Exhibit 76: Hospira opportunity growth assessment

  • Global Biologics and Biosimilars Market Professional Survey Report 2017
    Published: 16-Oct-2017        Price: US 3500 Onwards        Pages: 112
    This report studies Biologics and Biosimilars in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Pfizer - Roche - Amgen - AbbVie - Sanofi - J......
  • Global Adalimumab Biosimilar Sales Market Report 2017
    Published: 13-Oct-2017        Price: US 4000 Onwards        Pages: 116
    In this report, the global Adalimumab Biosimilar market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Adalimumab Biosimilar for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe ......
  • The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis
    Published: 13-Oct-2017        Price: US 4000 Onwards        Pages: 104
    The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation biologics. The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents. The psoriasis treatment market is dominated......
  • Global Adalimumab Biosimilar Market Research Report 2017
    Published: 04-Oct-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Adalimumab Biosimilar market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Adalimumab Biosimilar in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • United States Oncology Biosimilars Market Report 2017
    Published: 03-Oct-2017        Price: US 3800 Onwards        Pages: 104
    In this report, the United States Oncology Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rat......
  • Global Oncology Biosimilars Sales Market Report 2017
    Published: 28-Sep-2017        Price: US 4000 Onwards        Pages: 102
    In this report, the global Oncology Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Oncology Biosimilars for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan......
  • United States Biologics and Biosimilars Market Report 2017
    Published: 22-Sep-2017        Price: US 3800 Onwards        Pages: 113
    In this report, the United States Biologics and Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growt......
  • Global Biologics and Biosimilars Sales Market Report 2017
    Published: 19-Sep-2017        Price: US 4000 Onwards        Pages: 119
    In this report, the global Biologics and Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Biologics and Biosimilars for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe......
  • Global Oncology Biosimilars Market Research Report 2017
    Published: 18-Sep-2017        Price: US 2900 Onwards        Pages: 100
    In this report, the global Oncology Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Oncology Biosimilars in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs